{"id":3207,"date":"2026-03-10T15:42:13","date_gmt":"2026-03-10T15:42:13","guid":{"rendered":"https:\/\/www.europesays.com\/news\/3207\/"},"modified":"2026-03-10T15:42:13","modified_gmt":"2026-03-10T15:42:13","slug":"vertex-says-drug-reduced-marker-of-kidney-disease-in-late-stage-trial","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/news\/3207\/","title":{"rendered":"Vertex says drug reduced marker of kidney disease in late-stage trial"},"content":{"rendered":"

Vertex said Monday that a drug it secured as part of a $4.9 billion acquisition<\/a> successfully reduced by half a key marker of a kidney disease known as IgA nephropathy.<\/p>\n

The results, from a Phase 3 trial, match data from a study of Otsuka\u2019s recently approved Voyxact<\/a> and are numerically superior to data released last year by Vera Therapeutics<\/a>.<\/p>\n

All three companies have been racing to treat a disease that affects 330,000 people across the U.S. and Europe, according to Vertex\u2019s estimates, putting many at risk of developing end-stage renal disease. Analysts have projected Vertex\u2019s drug could eventually bring in $4 billion or more in annual sales.\u00a0<\/p>\n

STAT+ Exclusive Story<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\"STAT+\"\/<\/p>\n

\t\t\t\t\t
\n\t\t\t\t\t\t\"STAT+\"\/
\n\t\t\t\t\t<\/a><\/p>\n

\t\t\t\tThis article is exclusive to STAT+ subscribers
\n\t\t\t\tUnlock this article \u2014 plus daily coverage and analysis of the biotech sector \u2014 by subscribing to STAT+.<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\t\t\tIndividual plans<\/p>\n

\t\t\t\t\t\tGroup plans<\/p>\n

\t\t\t\tView All Plans<\/a><\/p>\n

\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n

\t\t\t\t\tSubscribe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Vertex said Monday that a drug it secured as part of a $4.9 billion acquisition successfully reduced by…\n","protected":false},"author":2,"featured_media":3208,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[1433,2861,8,9,1435,2400,7,2862],"class_list":{"0":"post-3207","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-top-stories","8":"tag-biotechnology","9":"tag-chronic-disease","10":"tag-headlines","11":"tag-news","12":"tag-pharmaceuticals","13":"tag-stat","14":"tag-top-stories","15":"tag-vertex"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@news\/116205646164533094","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/news\/wp-json\/wp\/v2\/posts\/3207","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/news\/wp-json\/wp\/v2\/comments?post=3207"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/news\/wp-json\/wp\/v2\/posts\/3207\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/news\/wp-json\/wp\/v2\/media\/3208"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/news\/wp-json\/wp\/v2\/media?parent=3207"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/news\/wp-json\/wp\/v2\/categories?post=3207"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/news\/wp-json\/wp\/v2\/tags?post=3207"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}